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Abstract
Background and Objectives: Preclinical studies have shown cannabidiol is protective in models of ischemic
stroke. Based on results from our recent systematic review, we investigated the effects of two promising neuro-
protective phytocannabinoids, cannabigerol (CBG) and cannabidivarin (CBDV), on cells of the blood–brain barrier
(BBB), namely human brain microvascular endothelial cells (HBMECs), pericytes, and astrocytes.
Experimental Approach: Cultures were subjected to oxygen-glucose deprivation (OGD) protocol to model is-
chemic stroke and cell culture medium was assessed for cytokines and adhesion molecules post-OGD. Astrocyte
cell lysates were also analyzed for DNA damage markers. Antagonist studies were conducted where appropriate
to study receptor mechanisms.
Results: In astrocytes CBG and CBDV attenuated levels of interleukin-6 (IL-6) and lactate dehydrogenase (LDH),
whereas CBDV (10 nM–10 lM) also decreased vascular endothelial growth factor (VEGF) secretion. CBDV
(300 nM–10 lM) attenuated levels of monocyte chemoattractant protein (MCP)-1 in HBMECs. In astrocytes,
CBG decreased levels of DNA damage proteins, including p53, whereas CBDV increased levels of DNA damage
markers. Antagonists for CB1, CB2, PPAR-c, PPAR-a, 5-HT1A, and TRPV1 had no effect on CBG (3 lM) or CBDV
(1 lM)-mediated decreases in LDH in astrocytes. GPR55 and GPR18 were partially implicated in the effects of
CBDV, but no molecular target was identified for CBG.
Conclusions: We show that CBG and CBDV were protective against OG mediated injury in three different cells
that constitute the BBB, modulating different hallmarks of ischemic stroke pathophysiology. These data enhance
our understanding of the protective effects of CBG and CBDV and warrant further investigation into these com-
pounds in ischemic stroke. Future studies should identify other possible neuroprotective effects of CBG and
CBDV and their corresponding mechanisms of action.
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Introduction
The blood–brain barrier (BBB) is a unique interface
that separates the central nervous system (CNS) and
the periphery, protecting the brain from damaging
components found in general circulation, namely pe-
ripheral leukocytes, macromolecules, and xenobiot-
ics.1,2 The barrier itself is formed by microvascular
endothelial cells, which are encompassed by pericytes,
and altogether surrounded by astrocyte end feet, which
cover 99% of BBB endothelia.3 Cerebral ischemia–
reperfusion (IR) initiates a plethora of inflammatory
signaling pathways, cytotoxic glutamate release, and
oxidative stress, all of which contribute to increases
in BBB permeability.4 This loss of BBB integrity
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ultimately causes uncontrolled immune infiltration
into the CNS that perpetuates neuronal injury and hin-
ders poststroke recovery. Although administration of
tissue plasminogen activator (tPA) and mechanical
thrombectomy are effective licensed therapies to dis-
solve or remove the culpable clot, at present, there
are no available approved therapies that mitigate post-
stroke injury.5
Cannabidiol (CBD), one of the chemicals found in
Cannabis sativa, has displayed a range of neuroprotec-
tive qualities, preventing neuronal loss,6,7 attenuating
astrocyte reactivity,8 and dampening the neuroinflam-
matory response.9 Unlike delta9-tetrahydrocannabinol
(D9-THC), CBD does not activate the central cannabi-
noid receptors, CB1 or CB2, but activates a plethora of
other targets including PPAR-c, TRPV1, and 5-HT1A
receptors.10–13 CBD has formulations (alone and with
D9-THC) licensed by GW pharmaceuticals to treat
rare childhood epilepsies and spasticity associated
with multiple sclerosis. The protective effects of CBD
in stroke models has been well documented,14 specifi-
cally CBD has been shown to reduce infarct volume,15,16
reduce glutamate toxicity,9,17 attenuate mitochondrial
dysfunction18 and glial activation.6,19 In a co-culture
BBB model CBD preserved barrier integrity after oxygen-
glucose deprivation (OGD), which was mediated at
least in part by PPAR-c and 5-HT1A receptors.
12
Cannabigerol (CBG) and cannabidivarin (CBDV)
are neutral cannabinoids present in cannabis and stud-
ies have found these compounds share similar pharma-
cological characteristics to CBD. Like CBD, they do not
produce feelings of euphoria and display antioxidant
and anti-inflammatory properties, as well as interacting
with a range of target proteins including TRPV1,13
PPAR-c,20 5-HT1A, and CB2.
21 Recently our group
conducted a systematic review focusing on the neu-
roprotective properties of minor phytocannabinoids
(other than D9-THC or CBD) and found that CBG
and CBDV show efficacy in models of Huntington’s
disease, Alzheimer’s, and epilepsy, with CBG mediating
its protective effects through PPAR-c activation,22 the
same mechanism by which we have shown that CBD
protects BBB integrity.12 However, despite these com-
pounds having neuroprotective effects in other models,
no studies have been conducted to test whether CBG
or CBDV are protective in IR injury.
In light of the above, we hypothesized these com-
pounds may exhibit protective properties at the
BBB in a stroke model. To test this, we treated cells of
the BBB with CBG or CBDV in vitro before an OGD
protocol and measured various proinflammatory cyto-
kines, adhesion molecules, and cell damage markers.
Materials and Methods
Materials
CBG and CBDV were kindly gifted by STI pharmaceu-
ticals. Both compounds were dissolved in 100% ethanol
to 10 mM and were stored at 20C. AM251, AM630,
GW6471, GW9962, O1918, CID16020046, SB366791
(Tocris, United Kingdom) were dissolved in dimethyl
sulfoxide as stock solutions of 10 mM. (S)-WAY100135
was dissolved in deionized water. Antagonists were stored
at 20C and dilutions were made fresh as required.
General cell culture
Human brain microvascular endothelial cells (HBMECs),
astrocytes, and pericytes (passages 3–6) were grown in
their respective medium and maintained at 37C in a
humidified incubator supplemented with 5% CO2.
HBMECs were cultured on fibronectin-coated plastic-
ware (2 lg/cm2), as per supplier recommendations.
Primary cells and medium were purchased from Scien-
Cell, United Kingdom.
OGD protocol
To simulate ischemic conditions, normal medium was
replaced with glucose free RPMI medium (Gibco,
United Kingdom) containing either CBG or CBDV
(10 nM to 10 lM), alongside a vehicle control (0.01%
ethanol). Cell culture plates were then placed in an
anoxic bag (BD GasPak, anaerobe) for 4 h (8 h for
astrocyte experiments) plus an additional 20 min to en-
sure anaerobic conditions. For vehicle normoxia, etha-
nol (0.01%) was added to the respective medium of
each cell type (ScienCell) and maintained in normal
oxygenated conditions. After OGD, medium was
aspirated and replaced with each cell types respective
medium (ScienCell) containing the relevant concentra-
tions of CBG or CBDV for a 20-h/16-h reperfusion pe-
riod. At 24 h, the medium was sampled, and cells were
lysed with RIPA buffer containing protease and phos-
phatase inhibitors (Sigma, United Kingdom; Thermo-
Fisher, United Kingdom). Medium and lysates were
stored at 80C for future analysis.
Total protein
To quantify total protein, a bicinchoninic acid (BCA)
protein assay was performed on cell lysates. A working
reagent of copper II sulfate and BCA (Sigma-Aldrich)
was prepared in a 1:50 ratio and added to wells. After
a 30-min incubation at 37C, plates were read at
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562 nm. Unknowns were extrapolated from a standard
curve of known concentrations of bovine serum album.
Unless otherwise stated, all secreted and intracellular
proteins were normalized to total protein.
Enzyme-linked immunosorbent assay
Medium samples were analyzed for various proinflamma-
tory cytokines including interleukin (IL)-6, IL-8, and adhe-
sion molecules including intracellular adhesion molecule
(ICAM)-1, vascular endothelial growth factor (VEGF),
monocyte chemoattractant protein (MCP)-1 using duo-
set enzyme-linked immunosorbent assay (ELISA) by
R&D systems, United Kingdom (DY206, DY208, DY720,
DY293B, and DY279). Raw values at 570 nm were sub-
tracted from values obtained at 450 nm, sample concentra-
tions were determined by extrapolating unknowns from
the 8-point standard curve (known concentrations).
Lactate dehydrogenase assay
A lactate dehydrogenase (LDH) assay was performed
to determine nonspecific damage induced by the
OGD protocol. A standard curve of known concen-
tration of nicotinamide adenine dinucleotide was
constructed as per manufacturer’s instructions. Fifty
microliters of standard or sample was aliquoted into
a 96-well plate and 50 lL of assay mix was added.
Plate absorbance was read at 450 nm and unknown
values were obtained from a standard curve.
DNA damage/genotoxicity assay
Astrocyte lysates post-OGD were analyzed using the
Milliplex DNA damage/Genotoxicity multiplex as-
say kit (Millipore, 48–621MAG) to detect changes in
DNA damage markers ataxia-telangiectasia mutated
(ATR-Total), checkpoint kinases 1, 2 (Chk1, Ser345
and Chk2, and Thr68), histone family member X
(H2A.X, Ser139), mouse double minute 2 homolog
(MDM2, total), cyclin-dependent kinase inhibitor 1
(p21, total), tumour protein (p53, Ser15). Kits were
performed according to manufacturer’s instructions.
Statistical analysis
All data are represented as the mean – standard error of
the mean, data were assessed for normality using the
D’Agostino–Pearson normality test and subsequently
analyzed using one-way analysis of variance with Dun-
nett’s post hoc analysis. All statistical analyses were
conducted using GraphPad prism (7/8) (Version 7.01;
GraphPad Software, Inc.), comparing either vehicle
normoxia or vehicle OGD with all other treatments.
A value of p < 0.05 was considered significant.
Results
HBMEC monocultures
Protein levels from HBMEC lysates were significantly
lower post-OGD compared with vehicle normoxia
wells ( p < 0.001). This was not affected by pretreatment
with CBDV or CBG (Supplementary Fig. S1C, F).
IL-6, ICAM-1, and MCP-1 were significantly in-
creased in cell culture medium 24 h after 4-h OGD
compared with normoxia vehicle ( p < 0.05; Fig. 1A–
F). Pretreatment with CBG (10 nM–10 lM) displayed
an overall trend to decrease IL-6 and 100 nM,
300 nM, and 10 lM CBG-treated wells were not statis-
tically significant to vehicle normoxia (Fig. 1A). CBG
pretreatment did not alter ICAM-1 and MCP-1 secre-
tion in response to OGD (Fig. 1B, C).
Pretreatment with CBDV (10 nM–1 lM and 10 lM)
did not attenuate IL-6 levels 24-h post-OGD. However,
3 lM CBDV was not significantly different from
vehicle normoxia (Figure 1D). Pretreatment with 3
and 10 lM CBDV significantly increased levels of
ICAM-1 24-h post-OGD ( p < 0.05, Fig. 1E). CBDV
(100 nM–10 lM) concentration-dependently reduced
levels of MCP-1, an effect that was significantly differ-
ent to vehicle OGD at 3 and 10 lM ( p < 0.05; Fig. 1F).
Pericyte monocultures
Protein levels from pericyte monocultures were not
significantly altered by the OGD protocol or drug treat-
ment (Supplementary Fig. S1A, D). A 4-h OGD in-
creased levels of IL-6, VEGF, and IL-8 measured in
cell culture medium 24-h post-OGD (Fig. 2A–F).
In pericyte monocultures, neither CBG nor CBDV
(10 nM–3 lM) altered IL-6 levels post-OGD; however,
both compounds increased IL-6 levels at 10 lM
( p < 0.0001; Fig. 2A, D). Pretreatment with CBG and
CBDV (10 nM–10 lM) did not alter levels of VEGF
(Fig. 2B, E).
At the lowest and highest concentrations tested,
CBG pretreatment increased IL-8 levels compared
with vehicle normoxia and vehicle OGD ( p < 0.05;
Fig. 2C). At 100 and 300 nM, CBG did not alter in-
creased levels of IL-8 produced by OGD (Fig. 2C).
CBDV did not affect IL-8 levels post-OGD, although
there was a trend to produce an increase in IL-8 at
10 lM (Fig. 2F).
Astrocyte monocultures
IL-6 levels were not statistically different to vehicle nor-
moxia 24 h after 4-h OGD (70.03 pg$mL normoxia vs.
65.29 pg$mL OGD, data not shown), but levels of IL-6
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FIG. 1. The effects of CBG and CBDV on HBMEC monocultures. Medium was analyzed for IL-6 (A, D),
ICAM-1 (B, E), and MCP-1 (C, F) 24 h after 4-h OGD. Data were normalized to total protein (calculated using
a BCA assay) and are given as a % change from the normoxia vehicle presented as means with error bars
representing SEM. n = 6–9 from three experimental repeats. *, Significant difference compared with
vehicle normoxia (vehicle N) (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). $p < 0.05, $$p < 0.01,
$$$p < 0.001, and $$$$p < 0.0001) significant difference to vehicle OGD, one-way ANOVA with Dunnett’s post
hoc analysis. ANOVA, analysis of variance; BCA, bicinchoninic acid; CBDV, cannabidivarin; CBG, cannabigerol;
HBMEC, human brain microvascular endothelial cell; ICAM-1, intracellular adhesion molecule-1; IL-6,
interleukin-6; MCP-1, monocyte chemoattractant protein-1; OGD, oxygen-glucose deprivation; SEM, standard
error of the mean.
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FIG. 2. The effects of CBDV and CBG on pericyte monocultures. Medium 24 h after 4-h OGD was analyzed
for IL-6, VEGF, and IL-8 (A–F). Data were normalized to total protein and are given as a % change from the
normoxia vehicle, presented as means with error bars representing SEM. n = 6–9 from 3 experimental
repeats. *, Significant difference compared with vehicle normoxia (vehicle N) (*p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001). $p < 0.05, $$p < 0.01, $$$p < 0.001, and $$$$p < 0.0001) significant difference
to vehicle OGD, one-way ANOVA with Dunnett’s post hoc analysis. VEGF, vascular endothelial growth factor.
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were significantly increased 24 h after 8-h OGD
( p < 0.01; Figure 3A and C). Therefore, subsequent ex-
periments in astrocytes were conducted using an 8-h
OGD protocol.
An 8-h protocol significantly decreased protein
levels in astrocyte cell lysates ( p < 0.01 versus vehicle
normoxia; Supplementary Fig. S1B, E). Treatment
with 10 lM CBG decreased protein content com-
pared with both vehicle OGD and vehicle normoxia
( p < 0.0001; Supplementary Fig. S1B). Pretreatment
with CBDV did not prevent the decrease in pro-
tein content caused by the 8-h OGD protocol ( p <
0.05 vs. vehicle normoxia); however, 30 nM, 1 and
10 lM CBDV did not exhibit a significant differ-
ence compared with vehicle normoxia (Supplemen-
tary Figure S1E).
Pretreatment with CBG 10 nM–3 lM attenuated astro-
cytic IL-6 levels ( p > 0.0001 vs. vehicle OGD; Fig. 3A);
however, at 10 lM CBG significantly increased IL-6
(Supplementary Fig. S2A). CBDV reduced levels of IL-6
compared with vehicle OGD at 30 nM ( p < 0.05), 1 lM
( p < 0.01), and 10 lM ( p < 0.05; Fig. 3C). CBDV at
300 nM and 3 lM also appeared to decrease IL-6 levels,
exhibiting no statistical difference to vehicle normoxia.
Astrocytic VEGF levels were significantly increased
post-OGD ( p < 0.0001; Fig. 3B, D). CBG pretreatment
appeared to attenuate VEGF levels at 100 nM and
3 lM, but this did not reach significance to vehicle
OGD (Fig. 3B). Conversely, 10 lM CBG significantly
increased VEGF compared with both vehicle normoxia
and vehicle OGD ( p < 0.001; Supplementary Fig. S2B).
Pretreatment with CBDV (10 nM–10 lM) decreased
FIG. 3. The effects of CBG and CBDV on astrocyte monocultures. (A-D) Medium 24 h after 8-h OGD were
analyzed for IL-6 and VEGF. Data were normalized to total protein and are given as a % change from the
normoxia vehicle, presented as means with error bars representing SEM. n = 5–9 from 3 experimental
repeats. *, Significant difference compared with vehicle normoxia (vehicle N) (*p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001). $p < 0.05, $$p < 0.01, $$$p < 0.001, and $$$$p < 0.0001) significant difference
to vehicle OGD, one-way ANOVA with Dunnett’s post hoc analysis.
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VEGF levels in a concentration-dependent manner. At
10 lM this was not significantly different to vehicle
normoxia and significantly different to vehicle OGD
( p < 0.0001; Fig. 3D).
LDH was significantly elevated in astrocyte medium
post-OGD ( p < 0.01; Fig. 4A, C). Pretreatment with 1
and 3 lM CBG significantly attenuated LDH activity
( p < 0.05; Fig. 4A); however, at 10 lM CBG signifi-
cantly increased LDH activity (Supplementary Fig. S2C).
CBDV exhibited a biphasic concentration response, de-
creasing LDH activity at lower (10 nM; p < 0.01) and
higher concentrations ( p < 0.05; 1 and 3 lM), but in-
creasing levels at 100 nM ( p < 0.001; Fig. 4C).
None of the antagonists tested blocked CBG (3 lM)-
mediated decreases in LDH; however, application of
CID1602 (antagonist for GPR55) appeared to potenti-
ate the effects of CBG ( p < 0.001; 3 lM CBG + CID1602
vs. vehicle OGD; Fig. 4B). In the presence of an-
tagonists for GPR55, CID1602 and O1918, CBDV
(1 lM)-mediated decreases in LDH were no longer
significantly different to vehicle OGD (Fig. 4D). In
addition, SB366791 appeared to potentiate the LDH-
reducing effects of CBDV ( p < 0.01; 1 lM CBDV
SB366791 vs. vehicle OGD, Fig. 4D).
As CBDV and CBG reduced cell damage in astro-
cytes, we next investigated whether these compounds
FIG. 4. The effects of CBG and CBDV treatment alone (A, B) and with antagonists (C, D) on LDH release
from astrocyte monocultures. Medium 24 h after 8-h OGD were analyzed LDH. Data were normalized to
total protein and are given as a % change from the normoxia vehicle, presented as means with error bars
representing SEM. n = 5–6 from 3 experimental repeats. *, Significant difference compared with vehicle
normoxia (vehicle N) (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). $p < 0.05, $$p < 0.01, $$$p < 0.001,
and $$$$p < 0.0001) significant difference to vehicle OGD, one-way ANOVA with Dunnett’s post hoc analysis.
LDH, lactate dehydrogenase.
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(at the most efficacious lower and higher concentrations
tested) influenced levels of DNA damage proteins. Lev-
els of DNA damage proteins, ATR, Chk1, Chk2,
H2A.X, and p53 were increased in astrocyte cell lysates
24 h after 8-h OGD. MDM2 showed a trend for in-
creasing post-OGD, but levels of p21 were not affected
(Fig. 5A–N). Application of CBG (1 lM) before OGD
significantly reduced levels of Chk1 and Chk2 com-
pared with OGD vehicle ( p > 0.01, p < 0.05; Fig. 5B,
C). In addition, CBG pretreatment at 10 nM, 1 lM,
and 3 lM decreased H2A.X levels that displayed
trend for increasing post-OGD ( p > 0.05; Fig. 5D). Lev-
els of p53 were also increased post-OGD ( p > 0.05) and
attenuated by CBG in a concentration-dependent man-
ner that was significant at 1 lM ( p > 0.05; Fig. 5K). By
contrast, CBDV (10 nM, 100 nM) increased levels of
ATR (p > 0.0001, p < 0.01; Fig. 5E) as well as increas-
ing levels of Chk1 at 100 nM (p < 0.05) and Chk2 at
10 nM (p < 0.01; Fig.5F). CBDV (100 nM and 1 lM)
also increased levels of H2A.X, p53 and MDM2
(p < 0.05; Fig. 5H, L, N).
Discussion
In this study we assessed whether non-euphoric phyto-
cannabinoids CBG and CBDV protected cells of the
BBB in a cellular model of ischemic stroke. Despite
promising preclinical data, drugs developed for one
or more of the hallmarks of stroke have failed once
they have reached clinical trials.23,24 Poor translational
efficacy is likely to stem from the multifactorial patho-
physiology of ischemic stroke and complicating factors
among elderly patients, which are often overlooked
in ischemic stroke modeling.25 These points empha-
size the need to generate new, effective therapies
for patients, which target multiple aspects of stroke
pathogenesis.26
CBD has been widely studied as a neuroprotectant,
partly because of its promiscuous pharmacology, toler-
able safety profile in humans and absence of euphoric
effects.10,27,28 However, other phytocannabinoids are be-
ginning to gain significant interest as therapeutic agents.
CBG has displayed prominent anti-inflammatory and
antioxidant capabilities20,29,30 and the antiepileptic
properties of CBDV have been well documented.31–33
Recently, CBDV has been shown to reduce inflamma-
tory cytokine release in a model of intestinal inflam-
mation.34 Our results demonstrate that CBDV and
CBG exhibit protective properties against OGD-induced
damage in astrocytes and HBMECs, modulating a range
of biochemical parameters measured post-OGD. For
CBDV, its cytoprotective effects appeared to partially in-
volve GPR55, but a target for CBG was not identi-
fied. These data warrant their further investigation
into these compounds as neuroprotectants and to assess
their clinical applicability, specifically, their efficacy in
in vivo models of ischemic stroke and whether they
are protective when applied post-OGD.
Post-cerebral ischemia and elevated levels of proin-
flammatory cytokine IL-6 are associated with increased
neuronal cell necrosis and are correlated with stroke se-
verity, increases in mortality rate, poor performance,
and functional disability.35–38 In this study, CBG and
CBDV significantly decreased levels of IL-6 in astro-
cytes, suggesting that like CBD, CBDV and CBG may
offer protection against inflammation caused by ische-
mic stroke.12 Increases in IL-6 post-ischemia have also
been implicated in BBB breakdown and tight junc-
tion remodeling, including reduced expression of VE-
cadherin, occludin, and claudin-5.39 Although there
was a trend for CBDV and CBG to attenuate IL-6 levels
in HBMECs, more pronounced reductions in IL-6 were
observed in astrocytes. Astrocytes provide biochemical
and mechanical support that help to maintain the BBB,
as well as providing neurovascular crosstalk between
neurons and cerebral blood vessels.40 Unlike in mono-
culture, in vivo, astrocyte endfeet are in direct contact
with endothelial cells; thus, modulating the astrocyte
inflammatory response in situ may act to preserve
BBB integrity indirectly by soluble factors secreted by
astrocytes or by preserving normal astrocyte function.
Mice lacking the receptor for adhesion molecule,
MCP-1 (CCR2), have significantly reduced infarct sizes
together with reduced BBB permeability and similarly,
MCP-1 knockout mice have a reduced influx of hema-
togenic cells from systemic circulation and improved
neurological outcome.41,42 Bonifacić et al. found a rela-
tionship between patients with poor outcomes 90 days
after stroke and elevated levels of MCP-1 and a recent
meta-analysis revealed that higher baseline circulating
levels of MCP-1 correlated with a higher risk of ische-
mic stroke.43,44 Our data show that CBDV concentra-
tion dependently decreased levels of MCP-1 secreted
by HBMECs when applied at the same time as initiating
OGD, suggesting that CBDV might offer protection
against MCP-1-related damage post-stroke and/or
offer protection in individuals at a higher risk of ische-
mic stroke. These data are also consistent with that of a
recent study showing that CBDV treatment attenuated
MCP-1 mRNA levels in colonic tissue post-colitis.34 Of
interest, this study also showed that CBDV was able to
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FIG. 5. The effects of CBG and CBDV on DNA damage markers (ATR [A,E], Chk1 [B,F], Chk2 [C,G], H2A.X
[D,H], MDM2 [I,L], p21 [J,M], and p53 [K,N] from astrocyte cell lysates, 24 h after 8-h OGD. Data were
normalized to total protein and are given as MFI as a % change from the normoxia vehicle (vehicle N);
means with error bars represent SEM. n = 6–8 from 3 experimental repeats. *, Significant difference
compared with vehicle normoxia (vehicle N) (*p < 0.05, **p < 0.01). $p < 0.05, $$p < 0.01 significant difference
to vehicle OGD, one-way ANOVA with Dunnett’s post hoc analysis. MFI, mean fluorescent intensity.
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reduce intestinal permeability, an effect that may be
replicated at the BBB, but this has yet to be investigated.
We also measured VEGF secreted by pericytes and
astrocytes post-OGD reperfusion as elevations in
VEGF are correlated with increased endothelial barrier
permeability post-ischemia.45–47 Li and co-authors
found that astrocyte-derived VEGF mediated endo-
thelial barrier disruption, which was associated with
decreases in occludin and claudin-5.47 Interestingly,
whilst CBG and CBDV did not affect pericyte-derived
VEGF, CBDV decreased VEGF secretion in astrocytes
in a concentration-dependent manner and CBG
exhibited a trend for decreasing VEGF at 100 nM and
3 lM. As VEGF is known to facilitate BBB opening
these compounds may offer protection against BBB
breakdown post-ischemia; however, the mechanisms
in which these compounds decrease VEGF remains
to be elucidated.
During IR injury cells undergo a combination of ap-
optosis and necrosis, causing various cellular compo-
nents to be released into the extracellular space. One
of these components, LDH, is often used as a marker
of cell damage. Previous studies have shown that IR
models cause LDH leakage into cell culture medium48,49
and clinically, LDH has been trialled as a marker of
ischemic severity.50,51 Pretreatment with CBDV and
CBG offset increases in LDH, suggesting both com-
pounds mitigate cellular damage produced by OGD
reperfusion. Application of receptor antagonists revealed
that CBDV appeared to mediate its effects on LDH lev-
els by GPR55; however, none of the antagonists tested
blocked the effect of CBG. This could be explained by
the nonspecific antioxidant properties of cannabinoids,
namely owing to their phenolic rings and hydroxyl
moieties.17,52 Indeed, previous studies have shown
that CBD increases antioxidant enzymes in BV2 micro-
glial cells,53 as well as attenuating oxidative stress
and increasing mitochondrial bioenergetics in OGD
reperfusion-damaged neurons.18 Similarly, CBD, CBDV,
and CBG were able to prevent oxytosis in a preclinical
drug screen for Alzheimer’s disease and CBG exhibited
antioxidant capacity in neuroblastoma cells.54,55 More
data are clearly needed on the specific and nonspecific
mechanisms in which these compounds mediate their
protective effects, particularly whether their antioxi-
dant status is responsible for reducing cell damage in
the context of ischemia.
Ischemia is a pathophysiological stressor and as a
consequence, nonspecific single- and double-strand
DNA breaks (ssDNA/dsDNA breaks) and replication-
associated DNA damage responses (DDRs) occur. DNA
damage can activate the DDR pathway and DDR re-
sponse proteins ATR, Chk1, Chk2, H2A.X, MDM2,
p21 and p53 that govern elements of DNA repair, cell
cycle arrest, apoptotic and necrotic cell death.56–59
These processes are central in IR injury and early stud-
ies found that neurons are the first to exhibit signs of
DNA damage (0.5–8 h reperfusion) followed by astro-
cytes (24 h reperfusion).60 Thus, we next investigated
the effect of CBDV and CBG on DDR proteins post-
OGD in astrocytes.
In support of previous studies, our OGD protocol
(and subsequent reperfusion period) increased levels
of almost all measured DDR proteins in astrocyte
monoculture lysates.61 In stroke patients, Huttner
and colleagues found evidence of ATM/ATR activity
in the penumbra of cortical neurons 7–10 days post-
ischemia.62 Studies have also shown p53 activation is
implicated in ischemia-induced neuronal cell death,
with elevated levels of p53 also present in reactive as-
trocytes and microglia.63,64 Ahn and colleagues found
that inhibition of p53 by pifithrin-a reduced OGD-
induced cell death in cultured astrocytes, and as a sec-
ondary effect reduced elevated levels of glutamate and
glial fibrillary acidic protein (GFAP), which were also
increased post-OGD.65 To our knowledge, this is the
first study to show that CBG pretreatment reduced lev-
els of Chk1, Chk2, H2A.X, and p53 in astrocytes post-
OGD. It is likely that these decreases in DNA damage
proteins were caused indirectly, possibly because of the
overall reductions in cellular damage and inflamma-
tion, as well as the known antioxidant properties of
CBG that have both been demonstrated in other stud-
ies.20,66 Nevertheless, direct modulation of these pro-
teins should not be ruled out particularly as PPAR-c,
a known target for phytocannabinoids, has been impli-
cated in ATM signaling and the DDR.67
Pretreatment with CBDV significantly increased ex-
pression of the majority of DNA damage proteins in as-
trocytes and exhibited a trend for increasing p21. CBD
was recently found to increase protein expression of
ATM and p21, but not p53 in an in vitro model of gas-
tric cancer, suggesting CBD promotes cell cycle arrest
at the G0–G1 phase.
68 Our data suggest that CBDV
acts in a similar manner; however, it is important to
emphasize that p21 has roles in both enhancing and
inhibiting apoptosis depending on the type of stressor;
thus, generating this response in a cancer cell model
will be different to responses of astrocytes subjected
to OGD. Low dose N-methyl-D-aspartate (NMDA) to
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simulate ischemic preconditioning was shown to increase
MDM2 protein expression, preventing p53 stabilization
in mouse cortical neurons and ischemia-induced apopto-
tic cell death.69 CBDV significantly increased levels of
MDM2, which is a key protein involved in p53 deg-
radation and thus promotion of cell survival. Future
studies should clarify the implications of CBDVs abil-
ity to increase levels of DNA damage proteins in ische-
mia and establish whether modulating DNA damage
and repair in astrocytes can influence post-stroke in-
jury and recovery.
Conclusions
This study provides novel data on the neuroprotective
and anti-inflammatory properties of CBG and CBDV
in an in vitro model of IR. These data, together with ev-
idence from other studies, corroborate the protective
properties of these compounds and further studies
are needed to elucidate the mechanism of action of
CBG and CBDV and whether they can modulate
BBB permeability in more clinically relevant in vivo
models of ischemic stroke. There is lack of effective
treatments for ischemic stroke, a condition that will in-
crease in prevalence in coming years, to which canna-
binoids may offer a unique therapeutic strategy.
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